Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8 +CD45RC − subset and lyse MHC class II + tumor cells

Abstract

Bacterial encoded superantigens (SA) are capable of activating and targeting cytolytic human and mouse T lymphocytes (CTL) to lyse major histocompatibility complex class II positive (MHC class II +) target cells. In this study both in vitro and in vivo activated rat CTL were directed against MHC II + tumor targets by bacterial encoded SA. Polyclonal in vitro activation of rat peripheral blood T lymphocytes generated CTL capable of killing MHC class II + human BSM cells coated by staphylococcal enterotoxin (SE) -A, -E, -D, and TSST-1 but not by SEB or SEC1-3. Allo selective peritoneal CTL generated by intraperitoneal stimulation with allogeneic spleen cells were directed against BSM cells by SEA, -D, and -E but not by SEB, SEC1-3 or TSST-1. Based on the above observations, and in order to locally activate CTL, SEA was chosen for in vivo priming of rats by intraperitoneal inoculation of the toxin. SEA injection generated highly cytolytic CTL, and maximum cytolytic responses were seen at 50–250 μg SEA per animal with a peak in response 48–72 hours after injection of the toxin. The cytolytic activity of peritoneal SEA reactive effector cells was confined to the TCRαβ + CD4 − CD8 + CD45RC − cell population. MHC class II − colon carcinoma cells were insensitive to lysis by SEA reactive CTL but colon carcinoma cells induced to express MHC class II by interferon-γ (IFN-γ) treatment were efficiently lysed in the presence of SEA. Comparison of rat and human MHC II + colon carcinomas revealed a peak in sensitivity to lysis at 10–100 ng SEA/ml for both tumor targets. These findings suggest that superantigens can be used in local immunotherapy of peritoneal tumors such as ovarial and colorectal carcinomatosis, with inducible or constitutive expression of MHC class II.